TrustCore Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

TrustCore Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$98.2K	Buy	340 +33	+11%	+$10.1K	0.01%	357
2022 Q3	$89K	Buy	307 +164	+115%	+$47.2K	0.01%	364
2022 Q2	$40K	Hold	143	–	–	﹤0.01%	502
2022 Q1	$37K	Hold	143	–	–	﹤0.01%	535
2021 Q4	$31K	Buy	143 +50	+54%	+$9.72K	﹤0.01%	537
2021 Q3	$17K	Hold	93	–	–	﹤0.01%	676
2021 Q2	$19K	Hold	93	–	–	﹤0.01%	639
2021 Q1	$20K	Hold	93	–	–	﹤0.01%	593
2020 Q4	$22K	Hold	93	–	–	﹤0.01%	548
2020 Q3	$25K	Hold	93	–	–	﹤0.01%	480
2020 Q2	$27K	Hold	93	–	–	﹤0.01%	486
2020 Q1	$22K	Hold	93	–	–	0.01%	470
2019 Q4	$20K	Sell	93 -8	-8%	-$1.62K	﹤0.01%	524
2019 Q3	$17K	Buy	101 +8	+9%	+$1.42K	﹤0.01%	552
2019 Q2	$17K	Hold	93	–	–	﹤0.01%	541
2019 Q1	$17K	Hold	93	–	–	﹤0.01%	467
2018 Q4	$15K	Hold	93	–	–	0.01%	248
2018 Q3	$18K	Hold	93	–	–	0.01%	477
2018 Q2	$16K	Buy	93 +29	+45%	+$4.5K	0.01%	480
2018 Q1	$10K	Buy	+64	New	+$10.5K	﹤0.01%	508

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TrustCore Financial Services's VRTX Position: Q4 2022 in Review

TrustCore Financial Services increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q4 2022, buying an estimated $10.1K and bringing the position to 340 shares worth $98.2K. The position accounts for 0.01% of the portfolio, ranked #357.

TrustCore Financial Services first reported a position in VRTX in Q1 2018 and has held it in 20 quarters since. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

TrustCore Financial Services held 340 shares of Vertex Pharmaceuticals worth $98.2K as of Q4 2022.
TrustCore Financial Services bought 33 Vertex Pharmaceuticals shares in Q4 2022, an estimated $10.1K.
Vertex Pharmaceuticals made up 0.01% of TrustCore Financial Services's portfolio in Q4 2022, its #357 holding.
TrustCore Financial Services first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 20 quarters since.
1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.